Trial Outcomes & Findings for A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies (NCT NCT02329847)

Last Updated: 2025-05-25

Results Overview

ORR is percentage of participants achieving a complete response (CR), CR with incomplete marrow recovery (CRi), nodular partial response (nPR) or PR. IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/L, platelets \>100\*10\^9/L, Hgb \>11 g/dL and absolute lymphocyte count \<4000/mcL; CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR- \>=50% drop in lymphocyte count from baseline or \<=4.0\*10\^9/L with following: \>=50% decrease in sum products of up to 6 lymph nodes, no new enlarged lymph nodes, When abnormal, \>=50% decrease in enlargement of spleen from baseline or normalization and a response in 1 of following: Neutrophils \>1.5\*10\^9/L, Platelets\>100000/mcL and Hgb\>11 g/dL or \>=50% improvement over baseline in all. This outcome measure was planned to be analyzed for specified arm only.

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

144 participants

Primary outcome timeframe

Up to 6 years 11 months

Results posted on

2025-05-25

Participant Flow

Participant milestones

Participant milestones
Measure	Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg Participants with chronic lymphocytic leukemia (CLL)/ follicular cell lymphoma (FL)/diffuse large B-cell lymphoma (DLBCL), received ibrutinib 420 milligrams (mg) capsule orally once daily starting from Day 1 of Cycle 1 up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilogram (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg Participants with FL/DLBCL, received ibrutinib 560 mg capsule orally once daily starting from Day 1 of Cycle 1 up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg Participants with CLL/small lymphocytic lymphoma (SLL) with deletion (del) 17p or 11q, received ibrutinib 420 mg orally once daily, starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg Participants with FL, received ibrutinib 560 mg orally once daily, starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg Participants with DLBCL, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg Participants with richter syndrome, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.
Overall Study STARTED	7	7	36	35	39	20
Overall Study Treated (Safety Analysis Set)	7	7	35	35	37	20
Overall Study COMPLETED	0	0	1	0	0	0
Overall Study NOT COMPLETED	7	7	35	35	39	20

Reasons for withdrawal

Reasons for withdrawal
Measure	Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg Participants with chronic lymphocytic leukemia (CLL)/ follicular cell lymphoma (FL)/diffuse large B-cell lymphoma (DLBCL), received ibrutinib 420 milligrams (mg) capsule orally once daily starting from Day 1 of Cycle 1 up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilogram (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg Participants with FL/DLBCL, received ibrutinib 560 mg capsule orally once daily starting from Day 1 of Cycle 1 up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg Participants with CLL/small lymphocytic lymphoma (SLL) with deletion (del) 17p or 11q, received ibrutinib 420 mg orally once daily, starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg Participants with FL, received ibrutinib 560 mg orally once daily, starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg Participants with DLBCL, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg Participants with richter syndrome, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.
Overall Study Death	4	4	22	12	20	13
Overall Study Lost to Follow-up	0	0	2	3	0	1
Overall Study Physician Decision	0	0	0	0	1	0
Overall Study Withdrawal by Subject	2	1	5	7	8	3
Overall Study Other	1	2	6	13	10	3

Baseline Characteristics

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg n=7 Participants Participants with chronic lymphocytic leukemia (CLL)/ follicular cell lymphoma (FL)/diffuse large B-cell lymphoma (DLBCL), received ibrutinib 420 milligrams (mg) capsule orally once daily starting from Day 1 of Cycle 1 up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilogram (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=7 Participants Participants with FL/DLBCL, received ibrutinib 560 mg capsule orally once daily starting from Day 1 of Cycle 1 up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg n=35 Participants Participants with CLL/small lymphocytic lymphoma (SLL) with deletion (del) 17p or 11q, received ibrutinib 420 mg orally once daily, starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=35 Participants Participants with FL, received ibrutinib 560 mg orally once daily, starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=37 Participants Participants with DLBCL, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=20 Participants Participants with richter syndrome, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Total n=141 Participants Total of all reporting groups
Age, Continuous	61 years STANDARD_DEVIATION 18.08 • n=5 Participants	65.9 years STANDARD_DEVIATION 13.96 • n=7 Participants	64.3 years STANDARD_DEVIATION 9.57 • n=5 Participants	61.3 years STANDARD_DEVIATION 11.94 • n=4 Participants	59.2 years STANDARD_DEVIATION 15.99 • n=21 Participants	64.9 years STANDARD_DEVIATION 11.19 • n=10 Participants	62.2 years STANDARD_DEVIATION 12.94 • n=115 Participants
Sex: Female, Male Female	4 Participants n=5 Participants	4 Participants n=7 Participants	9 Participants n=5 Participants	15 Participants n=4 Participants	10 Participants n=21 Participants	12 Participants n=10 Participants	54 Participants n=115 Participants
Sex: Female, Male Male	3 Participants n=5 Participants	3 Participants n=7 Participants	26 Participants n=5 Participants	20 Participants n=4 Participants	27 Participants n=21 Participants	8 Participants n=10 Participants	87 Participants n=115 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	3 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	4 Participants n=115 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	7 Participants n=5 Participants	7 Participants n=7 Participants	34 Participants n=5 Participants	31 Participants n=4 Participants	35 Participants n=21 Participants	20 Participants n=10 Participants	134 Participants n=115 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	2 Participants n=21 Participants	0 Participants n=10 Participants	3 Participants n=115 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants
Race/Ethnicity, Customized Asian	0 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	2 Participants n=21 Participants	0 Participants n=10 Participants	5 Participants n=115 Participants
Race/Ethnicity, Customized Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants
Race/Ethnicity, Customized White	7 Participants n=5 Participants	5 Participants n=7 Participants	35 Participants n=5 Participants	33 Participants n=4 Participants	34 Participants n=21 Participants	20 Participants n=10 Participants	134 Participants n=115 Participants
Race/Ethnicity, Customized More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants
Race/Ethnicity, Customized Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=10 Participants	1 Participants n=115 Participants
Race/Ethnicity, Customized Other	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	1 Participants n=115 Participants
Region of Enrollment AUSTRALIA	0 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	1 Participants n=4 Participants	8 Participants n=21 Participants	1 Participants n=10 Participants	12 Participants n=115 Participants
Region of Enrollment ISRAEL	6 Participants n=5 Participants	1 Participants n=7 Participants	4 Participants n=5 Participants	8 Participants n=4 Participants	6 Participants n=21 Participants	0 Participants n=10 Participants	25 Participants n=115 Participants
Region of Enrollment POLAND	0 Participants n=5 Participants	0 Participants n=7 Participants	18 Participants n=5 Participants	6 Participants n=4 Participants	6 Participants n=21 Participants	10 Participants n=10 Participants	40 Participants n=115 Participants
Region of Enrollment SPAIN	1 Participants n=5 Participants	3 Participants n=7 Participants	5 Participants n=5 Participants	6 Participants n=4 Participants	2 Participants n=21 Participants	4 Participants n=10 Participants	21 Participants n=115 Participants
Region of Enrollment TURKEY	0 Participants n=5 Participants	0 Participants n=7 Participants	6 Participants n=5 Participants	6 Participants n=4 Participants	8 Participants n=21 Participants	1 Participants n=10 Participants	21 Participants n=115 Participants
Region of Enrollment UNITED STATES	0 Participants n=5 Participants	3 Participants n=7 Participants	0 Participants n=5 Participants	8 Participants n=4 Participants	7 Participants n=21 Participants	4 Participants n=10 Participants	22 Participants n=115 Participants

PRIMARY outcome

Timeframe: Up to 6 years 11 months

Population: The all-treated population included all participants who had received at least 1 dose of study drugs (either ibrutinib or nivolumab). The ORR evaluation criteria were disease specific and hence the analysis was done as per disease cohorts for this outcome measure as pre-planned.

Outcome measures

Outcome measures
Measure	Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL) n=30 Participants Participants with CLL in Cohort A1 and B1, received ibrutinib 420 milligrams (mg) capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Follicular Lymphoma (FL) Participants with FL in Cohorts A1, A2, and B2, and who had histologically confirmed initial diagnosis of FL, received ibrutinib either 420 or 560 mg capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Diffuse Large B-cell Lymphoma (DLBCL) Participants with DLBCL in Cohorts A1, A2, and B3, and who had histologically confirmed disease with at least 1 measurable disease site, received ibrutinib either 420 or 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Richter Participants who had histologically confirmed Richter syndrome in Cohort B4 with at least 1 site of measurable disease, received ibrutinib 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg Participants with DLBCL, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg Participants with richter syndrome, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.
Overall Response Rate (ORR) as Assessed International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008: Disease Cohort	63.3 Percentage of Participants	—	—	—	—	—

PRIMARY outcome

Timeframe: Up to 6 years 11 months

ORR defined as percentage of participants achieving a CR, CRi, nPR or PR. As per Non-Hodgkin Lymphoma, Cheson 2014, CR is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is \>= 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. Progressive disease (PD) \>= 50% increase from nadir in the sum of the products of at least two lymph nodes, or appearance of a new lesion greater than 1.5 cm in any axis even if other lesions are decreasing in size. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. This outcome measure was planned to be analyzed for specified arms only.

Outcome measures

Outcome measures
Measure	Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL) n=6 Participants Participants with CLL in Cohort A1 and B1, received ibrutinib 420 milligrams (mg) capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Follicular Lymphoma (FL) n=40 Participants Participants with FL in Cohorts A1, A2, and B2, and who had histologically confirmed initial diagnosis of FL, received ibrutinib either 420 or 560 mg capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Diffuse Large B-cell Lymphoma (DLBCL) n=45 Participants Participants with DLBCL in Cohorts A1, A2, and B3, and who had histologically confirmed disease with at least 1 measurable disease site, received ibrutinib either 420 or 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Richter n=20 Participants Participants who had histologically confirmed Richter syndrome in Cohort B4 with at least 1 site of measurable disease, received ibrutinib 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg Participants with DLBCL, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg Participants with richter syndrome, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.
Overall Response Rate (ORR) as Assessed Non-Hodgkin Lymphoma (NHL), Cheson 2014: Disease Cohort	50.0 Percentage of Participants	32.5 Percentage of Participants	37.8 Percentage of Participants	65.0 Percentage of Participants	—	—

PRIMARY outcome

Timeframe: Up to 6 years 10 months

Population: The safety population included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs for the treatment phase included events with an onset date/time on or after the start of study intervention through end of study were considered as treatment-emergent.

Outcome measures

Outcome measures
Measure	Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL) n=7 Participants Participants with CLL in Cohort A1 and B1, received ibrutinib 420 milligrams (mg) capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Follicular Lymphoma (FL) n=7 Participants Participants with FL in Cohorts A1, A2, and B2, and who had histologically confirmed initial diagnosis of FL, received ibrutinib either 420 or 560 mg capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Diffuse Large B-cell Lymphoma (DLBCL) n=35 Participants Participants with DLBCL in Cohorts A1, A2, and B3, and who had histologically confirmed disease with at least 1 measurable disease site, received ibrutinib either 420 or 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Richter n=35 Participants Participants who had histologically confirmed Richter syndrome in Cohort B4 with at least 1 site of measurable disease, received ibrutinib 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=37 Participants Participants with DLBCL, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=20 Participants Participants with richter syndrome, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.
Percentage of Participants With Treatment-emergent Adverse Event (TEAEs): Study Cohort	100 Percentage of Participants	100 Percentage of Participants	100 Percentage of Participants	100 Percentage of Participants	97.3 Percentage of Participants	95.0 Percentage of Participants

SECONDARY outcome

Timeframe: Up to 6 years 11 months

Population: The all-treated population included all participants who had received at least 1 dose of study drugs (either ibrutinib or nivolumab) and achieved either PR or better (including PRL only for CLL participants).

DOR is defined as the interval between the date of initial documentation of a response including partial response with lymphocytosis (PRL) and date of first documented evidence of progressive disease or death or date of censoring. iWCLL 2008 criteria for progressive disease: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \>= 50% increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (\>=5\*10\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.

Outcome measures

Outcome measures
Measure	Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL) n=2 Participants Participants with CLL in Cohort A1 and B1, received ibrutinib 420 milligrams (mg) capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Follicular Lymphoma (FL) n=1 Participants Participants with FL in Cohorts A1, A2, and B2, and who had histologically confirmed initial diagnosis of FL, received ibrutinib either 420 or 560 mg capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Diffuse Large B-cell Lymphoma (DLBCL) n=26 Participants Participants with DLBCL in Cohorts A1, A2, and B3, and who had histologically confirmed disease with at least 1 measurable disease site, received ibrutinib either 420 or 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Richter n=12 Participants Participants who had histologically confirmed Richter syndrome in Cohort B4 with at least 1 site of measurable disease, received ibrutinib 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=15 Participants Participants with DLBCL, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=13 Participants Participants with richter syndrome, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.
Duration of Response (DoR): Study Cohort	11.5 Months Interval 2.4 to 20.7	NA Months Here 'NA' indicates that median and 95% CI could not be estimated due to less number of participants with events.	19.2 Months Interval 9.4 to 19.4	10.2 Months Interval 5.1 to 17.8	NA Months Interval 4.6 to Here 'NA' indicates that median and upper limit of 95% CI could not be estimated due to less number of participants with events.	6.9 Months Interval 1.3 to Here 'NA' indicates that upper limit of 95% CI could not be estimated due to less number of participants with events.

SECONDARY outcome

Timeframe: Up to 6 years and 11 months

Population: The all-treated population included all participants who had received at least 1 dose of study drugs (either ibrutinib or nivolumab) and met criteria for progressive disease. Here 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure.

Duration of stable disease or better was defined as duration from the start of the treatment until the criteria for progression were met. IWCLL 2008 criteria for progressive disease: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \>= 50% increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.

Outcome measures

Outcome measures
Measure	Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL) n=1 Participants Participants with CLL in Cohort A1 and B1, received ibrutinib 420 milligrams (mg) capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Follicular Lymphoma (FL) n=1 Participants Participants with FL in Cohorts A1, A2, and B2, and who had histologically confirmed initial diagnosis of FL, received ibrutinib either 420 or 560 mg capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Diffuse Large B-cell Lymphoma (DLBCL) n=5 Participants Participants with DLBCL in Cohorts A1, A2, and B3, and who had histologically confirmed disease with at least 1 measurable disease site, received ibrutinib either 420 or 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Richter n=7 Participants Participants who had histologically confirmed Richter syndrome in Cohort B4 with at least 1 site of measurable disease, received ibrutinib 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=1 Participants Participants with DLBCL, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg Participants with richter syndrome, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.
Duration of Stable Disease or Better: Study Cohort	24.8 Months Interval 24.8 to 24.8	20.8 Months Interval 20.8 to 20.8	17.38 Months Interval 14.0 to 21.6	14.55 Months Interval 12.7 to 20.4	14.1 Months Interval 14.1 to 14.1	—

SECONDARY outcome

Timeframe: Up to 6 years 11 months

Population: The all-treated population included all participants who had received at least 1 dose of study drugs (either ibrutinib or nivolumab) and met criteria for progressive disease.

PFS is defined as the duration from the date of first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death, whichever comes first. Participants who were progression-free and alive or had unknown status were censored at the last tumor assessment. IWCLL 2008 criteria for progressive disease: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \>= 50% increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.

Outcome measures

Outcome measures
Measure	Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL) n=6 Participants Participants with CLL in Cohort A1 and B1, received ibrutinib 420 milligrams (mg) capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Follicular Lymphoma (FL) n=5 Participants Participants with FL in Cohorts A1, A2, and B2, and who had histologically confirmed initial diagnosis of FL, received ibrutinib either 420 or 560 mg capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Diffuse Large B-cell Lymphoma (DLBCL) n=16 Participants Participants with DLBCL in Cohorts A1, A2, and B3, and who had histologically confirmed disease with at least 1 measurable disease site, received ibrutinib either 420 or 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Richter n=26 Participants Participants who had histologically confirmed Richter syndrome in Cohort B4 with at least 1 site of measurable disease, received ibrutinib 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=22 Participants Participants with DLBCL, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=11 Participants Participants with richter syndrome, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.
Progression-free Survival (PFS): Study Cohort	2.0 Months Interval 1.1 to 24.8	9.1 Months Interval 0.7 to 20.8	21.6 Months Interval 12.0 to 21.6	7.6 Months Interval 2.9 to 12.7	3.2 Months Interval 2.1 to Here 'NA' indicates that upper limit of 95% CI could not be estimated due to less number of participants with events.	5.0 Months Interval 2.4 to Here 'NA' indicates that upper limit of 95% CI could not be estimated due to less number of participants with events.

SECONDARY outcome

Timeframe: Up to 6 years 11 months

Population: The all-treated population included all participants who had received at least 1 dose of study drugs (either ibrutinib or nivolumab) and were responders.

OS was defined as duration from the date of first dose of study drug to the date of the participant's death.

Outcome measures

Outcome measures
Measure	Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL) n=4 Participants Participants with CLL in Cohort A1 and B1, received ibrutinib 420 milligrams (mg) capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Follicular Lymphoma (FL) n=3 Participants Participants with FL in Cohorts A1, A2, and B2, and who had histologically confirmed initial diagnosis of FL, received ibrutinib either 420 or 560 mg capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Diffuse Large B-cell Lymphoma (DLBCL) n=11 Participants Participants with DLBCL in Cohorts A1, A2, and B3, and who had histologically confirmed disease with at least 1 measurable disease site, received ibrutinib either 420 or 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Richter n=9 Participants Participants who had histologically confirmed Richter syndrome in Cohort B4 with at least 1 site of measurable disease, received ibrutinib 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=16 Participants Participants with DLBCL, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=8 Participants Participants with richter syndrome, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.
Overall Survival (OS): Study Cohort	12.4 Months Interval 2.0 to 28.8	NA Months Interval 0.8 to Here 'NA' indicates that median and upper limit of 95% CI could not be estimated due to less number of participants with events.	NA Months Interval 21.6 to Here 'NA' indicates that median and upper limit of 95% CI could not be estimated due to less number of participants with events.	NA Months Here 'NA' indicates that median and 95% CI could not be estimated due to less number of participants with events.	19.0 Months Interval 7.7 to Here 'NA' indicates that upper limit of 95% CI could not be estimated due to less number of participants with events.	10.3 Months Interval 4.8 to Here 'NA' indicates that upper limit of 95% CI could not be estimated due to less number of participants with events.

SECONDARY outcome

Timeframe: Up to 6 years 11 months

Population: The all-treated population included all participants who had received at least 1 dose of study drugs (either ibrutinib or nivolumab).

Percentage of participants with lymphoma-related symptoms were reported. These symptoms included B-symptoms, recurrent fever, night sweats, weight loss, other disease-related symptoms, itching, fatigue, physical discomfort and any other.

Outcome measures

Outcome measures
Measure	Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL) n=7 Participants Participants with CLL in Cohort A1 and B1, received ibrutinib 420 milligrams (mg) capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Follicular Lymphoma (FL) n=7 Participants Participants with FL in Cohorts A1, A2, and B2, and who had histologically confirmed initial diagnosis of FL, received ibrutinib either 420 or 560 mg capsules orally, daily starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilograms (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Diffuse Large B-cell Lymphoma (DLBCL) n=35 Participants Participants with DLBCL in Cohorts A1, A2, and B3, and who had histologically confirmed disease with at least 1 measurable disease site, received ibrutinib either 420 or 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Ibrutinib and Nivolumab: Richter n=35 Participants Participants who had histologically confirmed Richter syndrome in Cohort B4 with at least 1 site of measurable disease, received ibrutinib 560 mg capsules orally, daily starting on Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=37 Participants Participants with DLBCL, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=20 Participants Participants with richter syndrome, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.
Percentage of Participants With Lymphoma-related Symptoms: Study Cohort	14.3 Percentage of Participants	42.9 Percentage of Participants	74.3 Percentage of Participants	25.7 Percentage of Participants	54.1 Percentage of Participants	60.0 Percentage of Participants

Adverse Events

Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg

Serious events: 4 serious events

Other events: 7 other events

Deaths: 4 deaths

Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg

Serious events: 3 serious events

Other events: 7 other events

Deaths: 4 deaths

Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg

Serious events: 23 serious events

Other events: 35 other events

Deaths: 22 deaths

Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg

Serious events: 15 serious events

Other events: 35 other events

Deaths: 12 deaths

Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg

Serious events: 23 serious events

Other events: 35 other events

Deaths: 20 deaths

Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg

Serious events: 15 serious events

Other events: 19 other events

Deaths: 13 deaths

Serious adverse events

Serious adverse events
Measure	Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg n=7 participants at risk Participants with chronic lymphocytic leukemia (CLL)/ follicular cell lymphoma (FL)/diffuse large B-cell lymphoma (DLBCL), received ibrutinib 420 milligrams (mg) capsule orally once daily starting from Day 1 of Cycle 1 up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilogram (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=7 participants at risk Participants with FL/DLBCL, received ibrutinib 560 mg capsule orally once daily starting from Day 1 of Cycle 1 up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg n=35 participants at risk Participants with CLL/small lymphocytic lymphoma (SLL) with deletion (del) 17p or 11q, received ibrutinib 420 mg orally once daily, starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=35 participants at risk Participants with FL, received ibrutinib 560 mg orally once daily, starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=37 participants at risk Participants with DLBCL, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=20 participants at risk Participants with richter syndrome, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.
Infections and infestations Pneumocystis Jirovecii Pneumonia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Blood and lymphatic system disorders Anaemia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Blood and lymphatic system disorders Febrile Neutropenia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.0% 2/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Blood and lymphatic system disorders Neutropenia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Blood and lymphatic system disorders Pancytopenia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Blood and lymphatic system disorders Splenomegaly	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Cardiac disorders Atrial Fibrillation	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Cardiac disorders Cardiac Failure	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Cardiac disorders Cardiotoxicity	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Cardiac disorders Myocardial Infarction	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Eye disorders Cataract	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Abdominal Discomfort	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Abdominal Pain	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Colitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Diarrhoea	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Enterocolitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Gastric Haemorrhage	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Gastritis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Gastrointestinal Haemorrhage	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Gastrointestinal Inflammation	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Intestinal Obstruction	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Large Intestine Perforation	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Oesophageal Compression	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Pancreatitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Stomatitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Asthenia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Chest Pain	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Chills	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Fatigue	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders General Physical Health Deterioration	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Mucosal Inflammation	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Multiple Organ Dysfunction Syndrome	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Oedema Peripheral	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Pyrexia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Unevaluable Event	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Hepatobiliary disorders Bile Duct Stone	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Hepatobiliary disorders Biliary Obstruction	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Hepatobiliary disorders Cholangitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Hepatobiliary disorders Cholecystitis	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Hepatobiliary disorders Portal Vein Thrombosis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Immune system disorders Hypersensitivity	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Anal Abscess	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Arthritis Bacterial	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Bacteraemia	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Cellulitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Covid-19	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Encephalitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Enterococcal Bacteraemia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Erysipelas	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Gastroenteritis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Influenza	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Nasopharyngitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Otitis Media	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Otitis Media Chronic	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Pneumonia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.0% 2/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Pneumonia Bacterial	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Pneumonia Fungal	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Pneumonia Klebsiella	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Pneumonia Parainfluenzae Viral	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Respiratory Syncytial Virus Infection	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Respiratory Tract Infection Bacterial	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Rhinovirus Infection	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Sepsis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Septic Shock	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Upper Respiratory Tract Infection	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Urinary Tract Infection	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Urinary Tract Infection Bacterial	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Viral Upper Respiratory Tract Infection	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Wound Infection	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Injury, poisoning and procedural complications Pancreatic Injury	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Alanine Aminotransferase Increased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Immunoglobulins Decreased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Transaminases Increased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Diabetes Mellitus Inadequate Control	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Hyponatraemia	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Back Pain	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal Cell Carcinoma	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Leukaemic Infiltration	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant Neoplasm Progression	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Penile Squamous Cell Carcinoma	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal Neoplasm	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Nervous system disorders Migraine	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Nervous system disorders Transient Ischaemic Attack	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Renal and urinary disorders Acute Kidney Injury	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Renal and urinary disorders Haematuria	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Renal and urinary disorders Hydronephrosis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Renal and urinary disorders Renal Failure	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Renal and urinary disorders Urinary Retention	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Reproductive system and breast disorders Benign Prostatic Hyperplasia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Reproductive system and breast disorders Prostatomegaly	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Asphyxia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Chronic Obstructive Pulmonary Disease	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.0% 2/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Organising Pneumonia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Pleural Effusion	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Respiratory Arrest	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Respiratory Failure	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Rash Maculo-Papular	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Vascular disorders Aortic Aneurysm	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).

Other adverse events

Other adverse events
Measure	Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg n=7 participants at risk Participants with chronic lymphocytic leukemia (CLL)/ follicular cell lymphoma (FL)/diffuse large B-cell lymphoma (DLBCL), received ibrutinib 420 milligrams (mg) capsule orally once daily starting from Day 1 of Cycle 1 up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kilogram (kg) as an intravenous (IV) infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=7 participants at risk Participants with FL/DLBCL, received ibrutinib 560 mg capsule orally once daily starting from Day 1 of Cycle 1 up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg n=35 participants at risk Participants with CLL/small lymphocytic lymphoma (SLL) with deletion (del) 17p or 11q, received ibrutinib 420 mg orally once daily, starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=35 participants at risk Participants with FL, received ibrutinib 560 mg orally once daily, starting at 7 days prior to Day 1 of Cycle 1 as a run-in period and then daily thereafter up to 56 cycles (26 months). Participants also received nivolumab 3 mg/kg as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=37 participants at risk Participants with DLBCL, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.	Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg n=20 participants at risk Participants with richter syndrome, received ibrutinib 560 mg orally once daily, starting from Day 1 of Cycle 1 up to 56 cycles (26 months), along with nivolumab 3 mg/kg administered as an IV infusion on Day 1 of each cycle up to 56 cycles. Each cycle was of 14 days.
Infections and infestations Cellulitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Conjunctivitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.0% 2/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Immune system disorders Drug Hypersensitivity	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Immune system disorders Secondary Immunodeficiency	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Bronchitis	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Blood and lymphatic system disorders Anaemia	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	25.7% 9/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 5/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	29.7% 11/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	40.0% 8/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Blood and lymphatic system disorders Febrile Neutropenia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Blood and lymphatic system disorders Leukocytosis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Blood and lymphatic system disorders Lymphocytosis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Blood and lymphatic system disorders Lymphopenia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Blood and lymphatic system disorders Neutropenia	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	57.1% 20/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	20.0% 7/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	27.0% 10/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	40.0% 8/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Blood and lymphatic system disorders Thrombocytopenia	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	31.4% 11/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 5/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	18.9% 7/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	15.0% 3/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Cardiac disorders Atrial Fibrillation	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Cardiac disorders Atrioventricular Block First Degree	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Cardiac disorders Cardiac Failure	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Cardiac disorders Palpitations	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Endocrine disorders Euthyroid Sick Syndrome	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Endocrine disorders Hypothyroidism	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Eye disorders Eye Haemorrhage	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Eye disorders Lacrimation Increased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Eye disorders Miosis	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Abdominal Distension	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Abdominal Pain	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 5/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	13.5% 5/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Abdominal Pain Lower	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Abdominal Pain Upper	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Anal Ulcer	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Constipation	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	13.5% 5/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Diarrhoea	71.4% 5/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	37.1% 13/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	34.3% 12/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	32.4% 12/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	25.0% 5/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Dry Mouth	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Dyspepsia	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Dysphagia	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Gastric Fistula	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Gastrooesophageal Reflux Disease	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Gingival Bleeding	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Intra-Abdominal Haematoma	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Melaena	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Nausea	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	20.0% 7/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	24.3% 9/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Stomatitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.0% 2/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Toothache	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Gastrointestinal disorders Vomiting	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	16.2% 6/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Asthenia	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 5/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Chills	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Fatigue	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	42.9% 3/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	17.1% 6/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	40.0% 14/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	29.7% 11/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Gait Disturbance	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders General Physical Health Deterioration	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Generalised Oedema	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Inflammation	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Influenza Like Illness	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Mucosal Inflammation	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Non-Cardiac Chest Pain	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Oedema Peripheral	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	20.0% 7/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	15.0% 3/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Pain	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Peripheral Swelling	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
General disorders Pyrexia	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	28.6% 10/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 5/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	24.3% 9/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	30.0% 6/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Hepatobiliary disorders Hyperbilirubinaemia	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Covid-19	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Cytomegalovirus Infection Reactivation	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Folliculitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Fungal Skin Infection	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Gallbladder Abscess	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Gastroenteritis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Herpes Simplex	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Herpes Zoster	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Influenza	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Klebsiella Infection	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Laryngitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Lower Respiratory Tract Infection	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Lymphangitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Nasopharyngitis	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Oral Candidiasis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Oral Herpes	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Otitis Media	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Paronychia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.0% 2/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Periodontitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Pharyngitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Pneumonia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	13.5% 5/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Pneumonia Bacterial	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Pulpitis Dental	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Respiratory Tract Infection	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Rhinovirus Infection	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Sinusitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Tonsillitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Upper Respiratory Tract Infection	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	31.4% 11/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	28.6% 10/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	18.9% 7/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	35.0% 7/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Urinary Tract Infection	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.0% 2/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Viral Infection	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Viral Pharyngitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Viral Upper Respiratory Tract Infection	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Wound Infection	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Infections and infestations Wound Infection Staphylococcal	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Injury, poisoning and procedural complications Contusion	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Injury, poisoning and procedural complications Fall	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Injury, poisoning and procedural complications Limb Injury	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Injury, poisoning and procedural complications Nasal Injury	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Injury, poisoning and procedural complications Traumatic Haematoma	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Alanine Aminotransferase Increased	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	13.5% 5/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	20.0% 4/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Amylase Increased	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 5/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Aspartate Aminotransferase Increased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	20.0% 4/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Blood Alkaline Phosphatase	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Blood Alkaline Phosphatase Increased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Blood Bilirubin Increased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.0% 2/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Blood Creatine Phosphokinase Increased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Blood Creatinine Increased	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	13.5% 5/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Blood Lactate Dehydrogenase Increased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Blood Pressure Increased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Blood Thyroid Stimulating Hormone Increased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Blood Uric Acid Increased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Gamma-Glutamyltransferase Increased	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Lipase Increased	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	22.9% 8/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	13.5% 5/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	15.0% 3/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Neutrophil Count Decreased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Platelet Count Decreased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.0% 2/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Serum Ferritin Decreased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Investigations Weight Decreased	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Decreased Appetite	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.8% 4/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Dehydration	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Glucose Tolerance Impaired	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Hypernatraemia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Hypokalaemia	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	22.9% 8/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	17.1% 6/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	18.9% 7/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	25.0% 5/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Hypomagnesaemia	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 5/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Hyponatraemia	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Hypoproteinaemia	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Metabolism and nutrition disorders Iron Deficiency	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Arthralgia	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	28.6% 10/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 5/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	13.5% 5/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Back Pain	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	13.5% 5/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Bone Pain	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Groin Pain	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Joint Swelling	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Muscle Spasms	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	24.3% 9/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Muscular Weakness	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Musculoskeletal Chest Pain	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 5/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Pain in Extremity	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	17.1% 6/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Musculoskeletal and connective tissue disorders Tendonitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal Cell Carcinoma	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin Papilloma	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour Haemorrhage	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour Pain	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Nervous system disorders Dizziness	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Nervous system disorders Dizziness Postural	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Nervous system disorders Headache	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 5/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	13.5% 5/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Nervous system disorders Hypoaesthesia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Nervous system disorders Neuropathy Peripheral	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Nervous system disorders Paraesthesia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.0% 2/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Nervous system disorders Peripheral Sensory Neuropathy	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Nervous system disorders Sciatica	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Nervous system disorders Tremor	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Psychiatric disorders Anxiety	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Psychiatric disorders Depressed Mood	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Psychiatric disorders Depression	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Psychiatric disorders Insomnia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Renal and urinary disorders Acute Kidney Injury	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Renal and urinary disorders Dysuria	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Renal and urinary disorders Haematuria	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Renal and urinary disorders Oliguria	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Renal and urinary disorders Pollakiuria	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.0% 2/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Renal and urinary disorders Proteinuria	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Renal and urinary disorders Renal Failure	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Reproductive system and breast disorders Benign Prostatic Hyperplasia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Reproductive system and breast disorders Pelvic Pain	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Reproductive system and breast disorders Vaginal Haemorrhage	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Asthma	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Cough	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	57.1% 4/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	31.4% 11/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	13.5% 5/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	20.0% 4/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Dyspnoea	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.8% 4/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.8% 4/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Laryngeal Inflammation	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Nasal Congestion	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Organising Pneumonia	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 5/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Productive Cough	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Respiratory, thoracic and mediastinal disorders Upper-Airway Cough Syndrome	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Acne	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	28.6% 2/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Decubitus Ulcer	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Dermatitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Dermatitis Acneiform	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.1% 3/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Dermatitis Allergic	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Dry Skin	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Ecchymosis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Eczema	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.0% 2/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Erythema	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Ingrowing Nail	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Night Sweats	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Petechiae	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Pruritus	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	10.8% 4/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Rash	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	17.1% 6/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	22.9% 8/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	29.7% 11/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	20.0% 4/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Rash Erythematous	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Rash Maculo-Papular	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	8.6% 3/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Rash Papular	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Seborrhoeic Dermatitis	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Skin Exfoliation	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Skin Lesion	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Skin and subcutaneous tissue disorders Urticaria	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.7% 2/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Vascular disorders Haematoma	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 5/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Vascular disorders Haemorrhage	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.7% 1/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Vascular disorders Hypertension	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	11.4% 4/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Vascular disorders Hypotension	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	2.9% 1/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.4% 2/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	15.0% 3/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Vascular disorders Pallor	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Vascular disorders Phlebitis	14.3% 1/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).
Vascular disorders White Coat Hypertension	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/7 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/35 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	0.00% 0/37 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).	5.0% 1/20 • Up to 6 years 11 months All-cause mortality was assessed on all randomized participants. Serious adverse events and other adverse events were assessed on safety analysis set which included all participants who received at least 1 dose of study drugs (either ibrutinib or nivolumab).

Additional Information

Executive Medical Director

Janssen Research & Development, LLC

Phone: 844-434-4210

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.
Publication restrictions are in place

Restriction type: OTHER